Back to search
Smoldering Plasma Cell Myeloma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Smoldering Plasma Cell Myeloma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Smoldering Plasma Cell Myeloma trials you may qualify forBlood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the can…
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. D…
The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, i…
This prospective, multicenter, observational study aims to identify molecular and immunological markers associated with disease progression in patients with mon…
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering…
This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering mul…
The purpose of this study is to evaluate the real-world characteristics and outcomes of participants with smoldering multiple myeloma (SMM) overall and by high-…
The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom'…
Background: Multiple myeloma (MM) is a tumor in which malignant plasma cells accumulate in the bone marrow. It can cause organ damage and is not curable. Resea…